Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 9(1): 17872, 2019 Nov 25.
Article in English | MEDLINE | ID: mdl-31767913

ABSTRACT

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

2.
Sci Rep ; 9(1): 6427, 2019 04 23.
Article in English | MEDLINE | ID: mdl-31015537

ABSTRACT

We aimed to compare the efficacy and safety of Multipulse laser vaporesection of the prostate (MPVP) versus plasmakinetic resection of the prostate (PKRP) for treatment of patients with benign prostate obstruction (BPO) in a prospective trial. From January 2016 to April 2017, a total of 144 patients were included in the cohort study, of whom 73 patients underwent MPVP and 71 underwent PKRP. All patients received pre-operative evaluation and followed up at 1, 3, 6 and 12 months postoperatively. Baseline characteristics, perioperative data and postoperative outcomes were compared. Early (within 30 days postoperatively) and late complications were also recorded. Preoperative data, including age, prostate volume, international prostate symptom score (IPSS), International Index of Erectile Function Questionnaires (IIEF-5), the rate of anticoagulants use, Charlson comorbidity index were similar in two groups. Peri-operative parameters, including the rate of transfusion, and decrease in hemoglobin level were comparable. The operative time, the duration of catheterization and length of hospital stay were significantly shorter in the MPVP group. The voiding parameters and the quality-of-life scores (QoL) improved significantly in both groups postoperatively. There was a significantly difference in QoL at 1-year in the MPVP group (p < 0.001), under mixed model analysis with random effect and Bonferroni correction. There were no significant differences in improvement of IPSS, Qmax, IIEF-5, residual prostate volume ratio and PSA level reduction at the 1-year follow-up. MPVP was significantly superior to PKRP in terms of a reduction in overall complication rate (21.9% vs 45.0%, p = 0.004). Both treatments led to comparable symptomatic improvements. MPVP demonstrates satisfactory efficiency, shorter catheterization time and shorter hospital stay. Our data revealed that MPVP may be a promising technique which is safe and favorable alternative for patients with BPO.


Subject(s)
Laser Therapy/methods , Prostate/surgery , Prostatic Hyperplasia/surgery , Transurethral Resection of Prostate/methods , Aged , Dysuria/diagnosis , Dysuria/etiology , Dysuria/physiopathology , Hematuria/diagnosis , Hematuria/etiology , Hematuria/physiopathology , Humans , Laser Therapy/adverse effects , Lasers , Length of Stay/statistics & numerical data , Male , Middle Aged , Operative Time , Organ Size , Penile Erection/physiology , Postoperative Complications/diagnosis , Postoperative Complications/physiopathology , Prospective Studies , Prostate/pathology , Prostate/physiopathology , Prostatic Hyperplasia/pathology , Prostatic Hyperplasia/physiopathology , Surveys and Questionnaires , Transurethral Resection of Prostate/adverse effects , Treatment Outcome , Urethral Stricture/diagnosis , Urethral Stricture/etiology , Urethral Stricture/physiopathology , Urinary Incontinence, Urge/diagnosis , Urinary Incontinence, Urge/etiology , Urinary Incontinence, Urge/physiopathology , Urination/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...